• N-MYC/eIF4G1 Axis Controls inv(16) AML Survival via CBFβ-SMM

  2026-08-04

  The referenced study uncovers N-MYC as a critical driver of cell survival in inv(16) acute myeloid leukemia (AML), acting through transcriptional regulation of eIF4G1. By demonstrating that the CBFβ-SMMHC fusion protein maintains leukemogenesis via the N-MYC/eIF4G1 pathway, the work provides new mechanistic insight and research directions for targeted intervention in AML.

• Cycloheximide in Fibrosis & Protein Turnover: Mechanisms and

  2026-08-04

  Explore cycloheximide as a protein biosynthesis inhibitor in fibrosis and protein turnover studies. This in-depth article goes beyond apoptosis assays to reveal new mechanistic insights and protocol guidance, integrating recent breakthroughs in TGF-β signaling and practical research workflows.

• Rotigotine Hydrochloride: Mechanistic Insight and Strategy i

  2026-08-03

  This in-depth thought-leadership article bridges mechanistic understanding and strategic guidance for translational researchers leveraging Rotigotine hydrochloride, a dopamine D2/D3 receptor agonist, in Parkinson’s disease models. Addressing both motor and non-motor disease spectra, including lower urinary tract dysfunction, it synthesizes preclinical evidence, protocol recommendations, and competitive positioning, while clearly differentiating its scope from standard product summaries.

• Tumor-Targeted PAD4 Inhibition: Suppressing H3cit and NETs I

  2026-08-03

  This study demonstrates that meta-phenylboronic acid-modified PAD4 inhibitors, such as Compound 5i TFA, achieve highly selective tumor targeting and robust inhibition of the PAD4–H3cit–NETs pathway in neutrophils. The findings highlight a novel strategy for reducing tumor growth and metastasis by modulating tumor immune microenvironments while minimizing systemic toxicity.

• Senolytic Actions of L. plantarum DS0037 Exosome-like Nanove

  2026-08-02

  This study demonstrates that exosome-like nanovesicles (ELNs) derived from Lactobacillus plantarum DS0037 selectively induce apoptosis in senescent cells while modulating gene expression to improve skin cell function. These findings highlight the potential of microbial ELNs as targeted senotherapeutics and anti-aging cosmetic agents.

• Mtb Hijacks BMX Kinase to Inhibit Lysosomal Acidification

  2026-08-01

  This study elucidates how Mycobacterium tuberculosis (Mtb) deploys the secreted protein Chp2 to enhance BMX kinase-mediated phosphorylation of the host V-ATPase E1 subunit, thereby inhibiting lysosomal acidification and supporting intracellular survival. The findings identify BMX kinase as a pivotal regulator in the host-pathogen interface, highlighting a novel therapeutic target for host-directed tuberculosis interventions.

• PPACK Dihydrochloride: Precision Thrombin Inhibition in Rese

  2026-07-31

  PPACK Dihydrochloride delivers unparalleled selectivity and irreversibility for thrombin inhibition, making it an indispensable tool for blood coagulation and platelet aggregation studies. This article dissects advanced workflows, troubleshooting strategies, and the translational impact of the latest reference findings—empowering researchers to achieve reproducibility and mechanistic clarity.

• Rotigotine: Dopamine D2/D3 Receptor Agonist in PD Research

  2026-07-31

  Rotigotine sets the benchmark for dopamine D2/D3 receptor agonists in both in vitro and in vivo Parkinson’s disease research, uniquely enabling advanced neuroprotection and symptom modeling. Explore evidence-driven workflows, nanoparticle delivery innovations, and troubleshooting strategies that maximize reproducibility and translational value.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-07-30

  This study demonstrates that phenothiazines, including perphenazine, enhance macrophage antibacterial activity by inducing reactive oxygen species (ROS) production and autophagy. These findings offer mechanistic insight into host-directed antibacterial strategies, potentially informing new approaches to combat antibiotic-resistant intracellular pathogens.

• Continuous Dopaminergic Delivery: Rotigotine in PD and RLS T

  2026-07-30

  This review details the development and clinical evidence supporting the rotigotine transdermal system for sustained dopaminergic stimulation in Parkinson’s disease (PD) and restless legs syndrome (RLS). By overcoming pharmacokinetic limitations of oral agonists, rotigotine enables continuous receptor activation, yielding improvements in both motor and non-motor symptoms.

• K⁺ Channel Blockade Alters Renal Blood Flow in Septic Rats

  2026-07-29

  This study investigates how ATP-sensitive and calcium-activated potassium channel blockers affect renal blood flow in septic shock models, revealing that their inhibition, particularly when combined with vasopressors, can exacerbate renal hypoperfusion. These findings provide mechanistic insight into the risks of K⁺ channel modulation in sepsis and have direct implications for vascular biology research.

• Applied Angiotensin (1-7): Protocols, Signaling, and Optimiz

  2026-07-29

  Harness the full translational power of Angiotensin (1-7) by integrating robust, data-driven workflows and troubleshooting strategies for cellular and in vivo models. This guide merges recent mechanistic insights with practical protocols, empowering research in anti-fibrotic, metabolic, and neuroprotective domains.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-07-28

  APExBIO’s Anlotinib hydrochloride delivers superior inhibition of angiogenesis and tumor cell proliferation through precise ERK pathway targeting and multi-receptor blockade. This guide translates bench research and clinical findings into actionable workflows, troubleshooting tips, and protocol parameters for cancer research scientists.

• PPM-18 in Translational Inflammation Research: Workflow & Tr

  2026-07-28

  PPM-18 enables precise and robust inhibition of iNOS expression for advanced inflammation and sepsis research. This guide details protocol enhancements, troubleshooting, and strategic applications that leverage its unique action on NF-κB signaling.

• Rotigotine: Dopamine D2/D3 Receptor Agonist in PD Research

  2026-07-27

  Rotigotine stands out as a versatile dopamine D2/D3 receptor agonist, enabling robust Parkinson’s disease and neuroprotection research through validated cell-based and in vivo protocols. This article translates the latest analytical and workflow advances into actionable steps, ensuring reproducibility and precision for both novice and advanced labs.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page